Surgical Science Sweden AB (SE:SUS)
:SUS
Want to see SE:SUS full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.4Last Year’s EPS
-0.39Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a mixed but fundamentally constructive picture: operational performance and underlying demand appear healthy (underlying revenue +4%, strong cash generation SEK 65m, FX-adjusted adjusted EBIT ~16%), product launches and geographic momentum (notably EMEA/U.K. and ultrasound) support the growth thesis, and the robotics pipeline is expanding beyond a single customer. Main negatives are short-term and largely external: a material FX headwind (USD weakness), a known commercial reversion with Intuitive that will depress 2026 license revenues (estimated SEK 60–90m impact), and structural challenges in China and timing-related softness in Americas and some industry projects. On balance, the highlights outnumber the lowlights and management reiterated confidence in strategy and targets for 2027.Company Guidance
Underlying Revenue Growth After FX Adjustment
Reported sales were down 6% to ~SEK 235–236 million, but underlying business grew by 4% after stripping out a significant currency headwind (USD weakness).
Strong Cash Generation
Generated SEK 65 million from operating activities (versus -SEK 5 million in Q1 last year), leading to net positive cash flow of SEK 51 million for the quarter and SEK 668 million in cash on the balance sheet; company carries no debt.
Adjusted EBIT at Target Levels (FX-Adjusted)
Adjusted EBIT was SEK 28 million (12% reported). When restated for FX effects, adjusted EBIT was SEK 42 million or ~16%, described as 'right at our target level.'
Educational Products Momentum — Especially EMEA / U.K.
Educational Products grew 6% reported (14% in local currencies). EMEA revenue surged over 80%, driven by Eastern Europe; U.K. posted one of its best quarters ever with sterling sales exceeding total 2025 U.K. sales.
Ultrasound and Product Pipeline Progress
Strong quarter for ultrasound with accelerating adoption and product launches in endovascular simulation (pulmonary embolism) and ICE 3D; first products released on the shared technology platform following the Intelligent Ultrasound integration.
Robotics Market Opportunity and Diversification
Despite short-term license volatility, management highlighted growing license revenues from multiple robotics customers (not just Intuitive), an expanding pipeline (developing solutions for most of the top 20 robotics companies), and favorable industry approvals that increase long-term demand for training and simulation.
Operational and Margin Improvement Initiatives
Price increases (including one in April) continuing to be implemented; focus on gross-margin improvement and scaling production to reduce unit costs (new Tel Aviv production facility expected to go live in Q2).
Customer Retention and Development Business Quality
More than 70% of customers in active development projects are repeat clients, indicating strong retention and recurring demand in the Medical Device segment.
SE:SUS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:SUS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 20, 2026 | kr33.32 | kr37.58 | +12.79% |
Feb 19, 2026 | kr24.88 | kr29.10 | +16.96% |
Nov 13, 2025 | kr84.15 | kr74.20 | -11.82% |
Aug 21, 2025 | kr100.00 | kr100.60 | +0.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Surgical Science Sweden AB (SE:SUS) report earnings?
Surgical Science Sweden AB (SE:SUS) is schdueled to report earning on Aug 19, 2026, TBA (Confirmed).
What is Surgical Science Sweden AB (SE:SUS) earnings time?
Surgical Science Sweden AB (SE:SUS) earnings time is at Aug 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Surgical Science Sweden AB stock?
The P/E ratio of Surgical Science Sweden AB is N/A.
What is SE:SUS EPS forecast?
SE:SUS EPS forecast for the fiscal quarter 2026 (Q2) is 0.4.